VistaGen Therapeutics, Inc. (VTGN)

Market Cap	25.75M
Revenue (ttm)	-185,600
Net Income (ttm)	-64.69M
Shares Out	206.81M
EPS (ttm)	-0.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,199,575
Open	0.13
Previous Close	0.131
Day's Range	0.116 - 0.133
52-Week Range	0.08 - 2.11
Beta	0.50
Analysts	Buy
Price Target	0.23 (+91.5%)
Earnings Date	Nov 10, 2022

About VTGN

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder...

• Industry: Biotechnology
• Founded: 1998
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: VTGN

Financial Performance

In 2021, VTGN's revenue was $1.11 million, an increase of 1.78% compared to the previous year's $1.09 million. Losses were -$47.76 million, 166.3% more than in 2020.

Analyst Forecast

According to 10 analysts, the average rating for VTGN stock is "Buy." The 12-month stock price forecast is 0.23, which is an increase of 91.51% from the latest price.

Price Target

$0.23

(91.51% upside)

Analyst Consensus: Buy